Lin JL, Lin-Tan DT, Hsu KH, Yu CC
Published in the New England Journal of Medicine — the highest-impact medical journal in the world — this study examined 202 patients with chronic kidney disease who had no known history of lead exposure. Over 24 months of monitoring, 64 were found to have elevated body lead levels despite no occupational or obvious environmental exposure. These patients were then randomized to receive EDTA chelation or placebo for 27 months.
Kidney function improved significantly in the chelation group over 27 months. Critically, the researchers concluded that even low-level environmental lead exposure — the kind most adults have without realizing — accelerates kidney disease progression. EDTA chelation slowed this progression measurably.
Bottom line — In patients with chronic kidney disease and no known occupational lead exposure, EDTA chelation slowed the rate of kidney function decline over 27 months. The clinical takeaway is that low-level environmental lead exposure — the kind most adults carry — can accelerate kidney disease, and that chelation can measurably modify that trajectory in affected patients.